The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Accelus sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Accelus is a medical technology company that is focused on accelerating minimally invasive and endoscopic spine surgery through its novel spine products and solutions. The company’s product portfolio includes flarehawk7, flarehawk9, tihawk7, tihawk9, tihawk11, linesider spinal system posterior fixation, toro-l, and biologics. It also offers implants and instruments that enable complex diseases to be addressed by surgeons and develop new products. The company develops quality solutions for the unique needs of its customers. Accelus is headquartered in Palm Beach Gardens, Florida, the US.
The key metrics of Accelus related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Accelus is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Accelus.
For a detailed understanding of the performance of Accelus, buy the report here.